Head and neck cancer is the seventh most common type of cancer worldwide and comprise
of a diverse group of tumours affecting the upper aerodigestive tract. Although many different …

The epidermal growth factor receptor (EGFR) is a cell-surface receptor belonging to ErbB
family of tyrosine kinase and it plays a vital role in the regulation of cell proliferation, survival …

PURPOSE Nivolumab was assessed in patients with virus-associated tumors in the phase
I/II CheckMate 358 trial (ClinicalTrials. gov identifier: NCT02488759). We report on patients …

Background Results from a phase 2 trial of the TPEx chemotherapy regimen (docetaxel–
platinum–cetuximab) showed promising results, with a median overall survival of 14· 0 …

The major development of the past decade in the first-line treatment of recurrent and/or
metastatic squamous cell carcinoma of the head and neck (R/M SCCHN) was the …

Cetuximab remains to date the only targeted therapy approved for the treatment of head and
neck squamous cell carcinoma (HNSCC). The EGFR pathway plays a key role in the …

Head and neck cancers (HNC) represent the seventh most frequent cancer worldwide, with
squamous cell carcinomas as the most frequent histologic subtype. Standard treatment for …

Introduction: The majority of patients with locally advanced head and neck squamous cell
carcinoma (HNSCC) will recur. The treatment of patients with recurrent/metastatic (R/M …

The addition of cetuximab to platinum-based chemotherapy (cisplatin or carboplatin plus 5-
fluorouracil [5-FU]), followed by maintenance cetuximab until disease progression …

Cutaneous squamous cell carcinoma (cSCC) is the second most common skin cancer, and
its incidence is rising because of the aging population. Nectin cell adhesion molecule 4 …